Current stock page

Financial Data

SYRE Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

SYRESpyre Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$104.00+$1.09 (+1.06%)

Latest quote

  • Momentum
    81
  • Value
    44
  • Quality
    61
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$90.49M$0$0$0$0
Gross Profit$0$0$0$45.25M-$45.25M$0$0$0
Operating Income-$105.72M-$41.64M-$45.64M-$57.17M-$56.89M-$41.94M-$53.57M-$61.25M
Net Income-$96.12M-$36.2M-$69.01M-$62.53M-$11.18M-$36.72M-$44.77M-$56.3M
EPS-$0.94-$0.36-$0.74-$0.7-$0.15-$0.6-$0.13-$0.15
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$77.5M-$69.88M-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.2M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$77.5M-$69.88M-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.2M
Net Cash Provided By Operating Activities-$77.5M-$69.88M-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.2M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.1B$1.17B$763.95M$777.78M$504.6M$538.83M$569.78M$608.48M
Total Debt$0$0$0$0$0$0$0$0
Cash And Cash Equivalents$82.73M$162.01M$97.19M$85.72M$64.9M$81.66M$48.49M$89.42M
Total Liabilities$48.19M$71.86M$93.14M$62.55M$49.5M$83.06M$87.17M$90.68M
Total Stockholders Equity$1.05B$1.1B$670.81M$715.24M$455.1M$455.77M$482.61M$517.8M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.738.078.313.973.052.251.611.67
P/S ratio101.61———————
Debt To Equity00000000
Free Cash Flow Yield-2.72%-2.35%-3.33%-5.96%-11.66%-15.06%-21.92%-18.22%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.738.078.313.973.052.251.611.67
P/S ratio101.61———————
Return On Equity-25.09%-16.25%-26.75%-21.70%-32.73%-45.38%-43.29%-40.17%
Debt To Equity00000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-37.96x
Pb8.74x
EPS Growth Yoy-526.67%
Gross Margin50.00%
Operating Margin-276.45%
ROE-29.82%
ROIC-23.61%
Debt To Equity0
FCF Yield-2.52%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$104.00
Volume746,235
RSI (14)59.4
MACD4.23
MACD signal3.57
MACD histogram0.66
ADX (14)17.93
SMA (50)$91.48
SMA (200)$76.67
ATR (14)$5.07
Historical volatility (annualized)59.54%
Volume (20-day average)997,401

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score53/100
Beta1.69
Annual volatility66.66%
Max Drawdown-27.81%
Sharpe Ratio2.57
VaR (95%, 1-day)-4.85%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

SYRE Financial Data FAQ

What is Spyre Therapeutics, Inc.'s revenue?

Spyre Therapeutics, Inc.'s revenue is one of the core financial data points for SYRE. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Spyre Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Spyre Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is SYRE's EPS?

SYRE's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Spyre Therapeutics, Inc.'s net income?

Spyre Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Spyre Therapeutics, Inc. generate?

Free cash flow shows how much cash Spyre Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Spyre Therapeutics, Inc. have?

Cash and debt help frame SYRE's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.